Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy

J. W. Moul, B. Thrasher, F. Debruyne, J. Sylvester, W. Fair, D. Grignon

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Recurrence after local prostate cancer treatment detectable only by a rise in serum prostate specific antigen (PSA) is a very common problem facing clinicians. Given that the majority of these men are relatively young and otherwise healthy, treatment of PSA-only recurrence requires approaches that not only improve survival but also preserve quality of life. For radical prostatectomy patients, a PSA-only recurrence is broadly defined as persistent or rising PSA in the postoperative period. For radiation-treated patients, the 1997 American Society for Therapeutic Radiology and Oncology guidelines specify three consecutive elevations of PSA after the post-treatment nadir PSA is achieved. Traditional hormonal therapy is the mainstay of systemic treatment for PSA-only recurrence, although nontraditional approaches such as intermittent and oral-only hormonal therapy are under study.

Original languageEnglish (US)
Pages (from-to)267-271+273
JournalMolecular Urology
Volume4
Issue number3
StatePublished - Nov 13 2000

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy'. Together they form a unique fingerprint.

  • Cite this

    Moul, J. W., Thrasher, B., Debruyne, F., Sylvester, J., Fair, W., & Grignon, D. (2000). Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Molecular Urology, 4(3), 267-271+273.